Alleviating role of ketamine in breast cancer cell-induced osteoclastogenesis and tumor bone metastasis-induced bone cancer pain through an SRC/EGR1/CST6 axis Authors: Xiaomin Zhang, Yanmei Zhang, Wei Du Published: 2024 ABSTRACT AimsThe analgesic effect of ketamine in cancer pain remains controversial. This research investigates the role of ketamine in bone metastasis-induced cancer pain in breast cancer (BC) and its associated molecular network.MethodsBC cell lines MDA-MB-231 and ZR-75-1 were treated with ketamine and malignant behaviors were assessed through CCK-8, colony formation, and Transwell assays. To evaluate the pro-osteoclastic effect in vitro, BC cells were co-cultured with RAW 264.7 cells. Alterations in the expression of SRC proto-oncogene (SRC), early growth response 1 (EGR1), and cystatin E/M (CST6) were induced in BC cells using lentivirus. MDA-MB-231 cells were injected intracardially into nude mice to examine tumor bone metastasis in vivo. Molecular interactions between SRC and EGR1, as well as between EGR1 and CST6 were analyzed via immunoprecipitation and luciferase assays.ResultsKetamine treatment suppressed viability, proliferation, migration and invasiveness, epithelial-mesenchymal transition, and pro-osteoclastic effect in BC cells. Ketamine also reduced osteoclastogenesis and tumor bone metastasis burden and alleviated pain in nude mice. SRC was identified as a target of ketamine. Overexpression of SRC in BC cells blocked the effects of ketamine. SRC bound to the EGR1 promoter, suppressing EGR1 transcription, whereas EGR1 activated CST6 transcription. Either EGR1 or CST6 overexpression counteracted the function of SRC overexpression and decreased the viability of BC cells and their pro-osteoclastic effect in vitro and in vivo.ConclusionThis study demonstrates that ketamine alleviates BC cell-induced osteoclastogenesis and tumor bone metastasis by suppressing SRC and restoring the EGR1/CST6 axis.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12885-024-13290-7. Introduction Female breast cancer (BC) represents the most commonly diagnosed cancer worldwide and the leading cause of cancer-related deaths among women [1]. The primary cause of mortality is tumor metastases at distant sites rather than the primary tumors [2]. Bones are the most frequent sites of metastasis, with approximately 55–75% of BC patients developing bone metastases [3, 4], significantly impacting their quality of life and decreasing overall survival [5]. Clinically, bone metastases result in several complications, including pain, pathological fractures, spinal cord compression, and hypercalcemia [6]. A delicate balance between osteoclasts and osteoblasts in the dynamic bone microenvironment is crucial for maintaining bone turnover and integrity [7]. The formation of metastatic lesions can disrupt this balance and create a vicious cycle that further aggravates both bone destruction and tumor progression [6]. Given the high incidence of bone metastasis in patients with advanced BC, managing bone metastasis presents a challenging yet promising area for clinical intervention. Analgesic drugs, particularly opioids, have been widely used to manage moderate or severe cancer-related pain [8, 9]. Ketamine is a noncompetitive N-methyl D-aspartate receptor antagonist. Ketamine can be administered through various routes and is known for its rapid onset and short elimination half-life. Its metabolism primarily occurs through oxidation by the cytochrome P450 enzyme family, producing metabolites such as norketamine, 6-hydroxyketamine, and 4-hydroxyketamine, with norketamine retaining pharmacological activity [10]. Intravenous subanesthetic doses of ketamine are well tolerated, typically resulting in few adverse events, and exhibit side effects that are generally less severe than those associated with traditional analgesics like morphine [11, 12]. Ketamine has been demonstrated as an effective option or as an adjuvant to opioids for the management of cancer pain [13]. The analgesic effect of ketamine is mainly due to its ability to block NMDA receptors, which reduces the excitability of central neurons and, consequently, lowers pain impulse conduction [14]. Additionally, ketamine can inhibit glial cell activation and diminish neuroinflammation [14]. Moreover, ketamine has also been reported to play anti-tumorigenic roles in BC by suppressing cell proliferation and inducing apoptosis and ferroptosis in cancer cells [15]. This work focuses on the role of ketamine in bone metastasis and bone pain in BC. Publicly accessible GEO datasets (https://www.ncbi.nlm.nih.gov/gds/?term=) and other web-based online bioinformatics systems are advanced and convenient tools for screening hub genes related to specific disorders [16, 17]. In the early stages of this research, we performed integrated bioinformatics analyses and identified SRC proto-oncogene, non-receptor tyrosine kinase (SRC) as a candidate hub protein of ketamine. We also identified early growth response 1 (EGR1) as a target transcript of SRC and cystatin E/M (CST6) as a candidate target of EGR1. SRC, a well-studied member of the Src family kinases (SFKs), has been found at elevated protein levels in various cancer types [18]. It interacts with multiple cellular factors, including FAK, steroid hormone receptors, integrins, and epidermal growth factor receptors, promoting proliferation and metastasis [18, 19]. Inhibition of SFKs has also been linked to reduced motility and invasiveness in BC cells [20]. EGR1 is an important transcription factor within the EGR family, containing both activation and repression regions that allow it to bind specifically to target genes and manipulate gene expression [21]. EGR1 can act as either a tumor suppressor or promoter, depending on the tumor type, and plays key roles in proliferation, invasion, and metastasis [21]. Moreover, increased EGR1 levels have been associated with reduced skeletal metastasis in BC [22]. Similarly, CST6 loss frequently occurs during BC progression [23]. Increased CST6 secretion by BC cells has been shown to suppress osteoclastogenesis and tumor bone metastasis [24]. Taken together, the present research was launched to validate if ketamine can affect the SRC/EGR1/CST6 axis, influencing bone metastasis and bone cancer pain in BC. Materials and methods Bioinformatics The GSE103357 dataset includes two primary breast cancer tumor samples and three cell line samples derived from bone metastases, using the primary tumors as the control group. The GSE92298 dataset comprises two parental breast cancer T47D cell samples and two bone metastasis T47D cell samples, with the parental samples serving as the control. GEO2R software was employed to analyze differentially expressed genes in the datasets, applying a screening threshold of p < 0.05. Drugbank (https://go.drugbank.com/), SwissTargetPrediction (http://www.swisstargetprediction.ch/index.php), and Super-PRED (https://prediction.charite.de/ index.php) databases to predict ketamine’s downstream targets. Venn analysis was conducted to identify common downstream targets of ketamine and the intersection between the differentially expressed genes in the GSE103357 and GSE92298 datasets. A protein-protein interaction (PPI) network based on these candidate factors was constructed via the STRING system (https://cn.string-db.org/). The downstream targets of the transcription factor SRC or EGR1 were predicted in hTFtarget (http://bioinfo.life.hust.edu.cn/hTFtarget). Furthermore, Venn analysis was also performed to explore the downstream targets of the transcription factor SRC and their intersection with the differentially expressed genes from the GSE103357 and GSE92298 datasets. Pathway enrichment analysis was conducted using the Metascape system (https://metascape.org/gp/index.html#/main/ step1). The GEPIA (http://gepia.cancer-pku.cn/detail.php) and Starbase (https://starbase.sysu.edu.cn/index.php) databases were leveraged to investigate the correlation between SRC and EGR1 expression in breast cancer. Cell culture Human BC cell lines MDA-MB-231 (CL-0150B) and ZR-75-1 (CL-0247) and mouse monocytes/macrophages RAW 264.7 (CL-0190) were procured from Procell Life Science & Technology Co., Ltd. (Wuhan, Hubei, China). All cells were cultured in Dulbecco’s modified Eagle’s medium along with 10% fetal bovine serum and antibiotics. The culture condition was maintained at 37℃ with 5% CO2. The cell lines were checked for mycoplasma contamination once a month. The culture media were replaced with antibiotic-free medium 48 h prior to testing, using a mycoplasma PCR detection kit (Sigma-Aldrich, USA). No mycoplasma contamination was detected during cell culture. Lentivirus infection Lentivirus vectors and their carried plasmids including overexpression (oe)-Luciferase, oe-SRC, oe-EGR1, oe-CST6, and the negative control (NC) were purchased from VectorBuilder Inc. (Guangzhou, Guangdong, China). 2 × 105 BC cells were seeded in six-well plates. When the cell confluence reached 60%, lentivirus solution was added to the plates for cell infection. The multiplicity of infection (MOI) for the MDA-MB-231 and ZR-75-1 cells was set at 10, with the lentivirus amount adjusted according to this MOI. After 48 h, stably infected (transfected) cells were screened by the addition of Puromycin (5 µg/mL). Cell counting kit-8 (CCK-8) method Approximately 3 × 103 BC cells were seeded into 96-well plates and treated with specific doses (0, 2, 5 and 10 µM) of ketamine for 48 h, followed by the addition of 100 µL CCK-8 reagent (HY-K0301, MedChemExpress, Monmouth Junction, NJ, USA) for 2 h of incubation. Thereafter, optical density at 450 nm was analyzed by microplate reader to evaluate the cell viability. Colony formation assay Approximately 1 × 103 BC cells were resuspended in a complete medium and cultured in six-well plates at 37℃ with 5% CO2 for two weeks. After that, the culture medium was discarded, and the cells were washed, fixed with paraformaldehyde, and stained with crystal violet. The number of formed cell colonies was calculated under microscopy. Transwell assays Migration and invasiveness of BC cells were analyzed by Transwell assays. For invasiveness detection, the Transwell apical chambers were pre-coated with Matrigel. Pre-coating with Matrigel was not necessary for migration assays. Approximately 2 × 104 cells were resuspended in apical chambers, and the basolateral chambers were added with the serum-containing complete medium as an attractant. Cells were placed in a 37℃ incubator. After 24 h, cells migrated to or invaded the basolateral chambers were fixed, stained with crystal violet, and counted under microscopy. Osteoclastic differentiation induction in vitro The treated BC cells were co-cultured with RAW 264.7 cells in a Transwell system (0.4-µm plates) to examine the impact of cancer cells on osteoclastic differentiation of RAW 264.7 cells. Specifically, 1 × 104 RAW 264.7 cells were cultured in the basolateral compartment of 24-well plates overnight. The medium was supplemented with 20 ng/mL macrophage colony-stimulating factor and 20 ng/mL RANKL to induce osteoclastic differentiation. The following day, approximately 2 × 103 BC cells were added to the apical wells. After one day of co-culture, the system was treated with either 5 µM ketamine or an equivalent volume of phosphate-buffered saline (PBS). After 5 d, the expression of osteoclast marker tartrate-resistant acid phosphatase (TRAP) was analyzed using quantitative polymerase chain reaction (qPCR). Additionally, another group of RAW 264.7 cells was co-cultured with the culture supernatant (conditioned medium; CM) from BC cells. MDA-MB-231 or ZR-75-1 were seeded in 24-well plates and treated with ketamine. After 48 h, the culture supernatant was collected and centrifuged at 500 g for 5 min. The resulting supernatant was then used to co-culture with RAW 264.7 cells for 6 d. The expression of TRAP was also analyzed via qPCR. RNA isolation and quantification Total RNA from the cells was extracted using TRI reagent (T9424, Sigma-Aldrich). After confirming the concentration and purity, the isolated RNA was reverse-transcribed into cDNA using the PrimeScript™ RT reagent Kit with gDNA Eraser (RR047A, Takara Holdings Inc., Kyoto, Japan). The qPCR analysis was conducted subsequently using the TB Green® Premix Ex Taq™ II (RR820Q, Takara). Gene expression was evaluated relative to the endogenous control, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), using the 2−ΔΔCt method. The primers included: human EGR1 (F): 5ʹ-AGCAGCACCTTCAACCCTCAGG-3ʹ, human EGR1 (R): 5ʹ-GAGTGGTTTGGCTGGGGTAACT-3ʹ; human CST6 (F): 5ʹ-ACTTCCTGACGATGGAGATG GG-3ʹ, human CST6 (R): 5ʹ-CAAGGACCTCAAAGTCACAGCG-3ʹ; human GAPDH (F): 5ʹ-GTCTCCTCTGACTTCAACAGCG-3ʹ, human GAPDH (R): 5ʹ-ACCACCCTGTTGCTGTAG CCAA-3ʹ; mouse TRAP (F): 5ʹ-ACCAGCAAGGATTGCGAGGCAT-3ʹ, mouse TRAP (R): 5ʹ-GGATGACAGACGGTATCAGTGG-3ʹ; mouse CTR (F): 5ʹ-GCAACGCTTTCACTTCTGAG A-3ʹ, mouse CTR (R): 5ʹ-GTTCCCACTGCATTGTCCACA-3ʹ; mouse CTSK (F): 5ʹ-GAAGAAG ACTCACCAGAAGCAG-3ʹ, mouse CTSK (R): 5ʹ-TCCAGGTTATGGGCAGAAGCAG-3ʹ; mouse GAPDH (F): 5ʹ-CATCACTGCCACCCAGAAGACTG-3ʹ, mouse GAPDH (R): 5ʹ-ATGCC AGTGAGCTTCCCGTTCAG-3ʹ. Western blot (WB) analysis Total protein was extracted from BC cells and the cell culture supernatant using the RIPA lysis buffer (C500005, Sangon Biotech Co., Ltd., Shanghai, China). The protein concentration was measured with a bicinchoninic acid (BCA) kit (C503021, Sangon Biotech). The protein samples were separated by gel electrophoresis and transferred onto polyvinylidene fluoride membranes, which were blocked with 5% non-fat milk for 45 min. Primary antibodies were applied overnight at 4℃. The following day, membranes were incubated with a horseradish peroxidase-conjugated secondary antibody (1:10,000, ab6721, Abcam Inc., Cambridge, MA, USA) at room temperature for 40 min. Subsequently, the membranes were treated with an enhanced chemiluminescence reagent (C510043, Sangon Biotech) to visualize the protein bands. Protein expression levels were analyzed relative to the control protein GAPDH using ImageJ. The primary antibodies used included: E-cadherin (1:1,000, 3195, Cell Signaling Technology, Beverly, MA, USA), N-cadherin (1:3,000, 22018-1-AP, Proteintech Group, Inc., Wuhan, Hubei, China), Vimentin (1:1,000, 5741, Cell Signaling Technology), SRC (1:1,000, 2191, Cell Signaling Technology), EGR1 (1:1,000, MA5-15008, Thermo Fisher Scientific, Rockford, IL, USA), CST6 (1:800, C4746, Sigma-Aldrich), and GAPDH (1:1,000, 2118, Cell Signaling Technology). Chromatin immunoprecipitation (ChIP)-qPCR Binding interactions between SRC and EGR1 promoter and between EGR1 and CST6 promoter were validated using a ChIP kit (17–408, Sigma-Aldrich). In short, BC cells were treated with 1% formaldehyde to crosslink protein and DNA, followed by termination of crosslinking with a final concentration of 0.125 M glycine. The cells were then lysed, and the lysates were ultrasonicated (25% power for 4.5 s, with 9-s intervals, repeated a total of 14 times) to fragment the DNA. The samples were mixed with SRC antibody (1:100, 2191, Cell Signaling Technology), EGR1 antibody (1:100, MA5-15008, Thermo Fisher Scientific), or control antibody IgG for immunoprecipitation. The immunocomplexes were de-crosslinked using Proteinase K, and the DNA was purified for qPCR analysis. Dual-luciferase reporter gene assay The binding sequences between the SRC and EGR1 promoters and between EGR1 and CST6 promoters were predicted using the hTFtarget system (http://bioinfo.life.hust.edu.cn/hTFtarget/#!/tf). Wild-type (WT) EGR1 and CST6 promoter sequences containing the predicted binding sequences, as well as mutant-type (MUT) sequences, were inserted into pGL3-Basic luciferase vectors. The constructed vectors were co-transfected with oe-NC, oe-SRC, or oe-EGR1 into MDA-MB-231 and ZR-75-1 cells. After 48 h, luciferase activity in the cells was analyzed using the dual-luciferase reporter gene assay system (E1910, Promega). Animals Six- to eight-week-old BALB/c nude mice were purchased from Charles River Laboratory Animal Technology Co., Ltd. (Beijing, China). The animals were used in accordance with protocols approved by the Animal Ethics Committee of China Medical University and followed the Guide for the Care and Use of Laboratory Animals (NIH). We also adhered to the ARRIVE guidelines and provided the necessary Checklist (CMUXN2023089). The mice were assigned to eight groups: Saline, Ketamine, Ketamine + oe-NC, Ketamine + oe-SRC, Ketamine + oe-SRC + oe-NC, Ketamine + oe-SRC + oe-EGR1, Ketamine + oe-SRC + oe-NC, and Ketamine + oe-SRC + oe-CST6, with five mice in each group. All mice were anesthetized using 3% isoflurane [25], followed by the injection of 1 × 105 luciferase-labeled MDA-MB-231 cells (resuspended in 100 µL PBS) with different transfection treatments into their left ventricle to induce bone metastasis [26]. After cell injection, the mice received an intravenous injection of either 10 mg/kg ketamine or an equal volume of normal saline through the tail vein. Subsequently, the mice were intraperitoneally injected with 150 mg/kg D-Luciferin, and the progression of bone metastasis in the mouse limbs was assessed weekly using bioluminescence imaging (BLI) [27]. The experiments were ended by week 5 after tumor cell injection. The mice were euthanized using an intraperitoneal injection of 150 mg/kg pentobarbital sodium, and their bone tissues were collected for hematoxylin and eosin (HE) staining and TRAP staining. Pain-related behavioral tests The discomfort of mice was evaluated by measuring the paw withdrawal threshold (PWT) in response to Von Frey hair stimulation and observing spontaneous flinching, as previously described [28, 29]. All behavioral assessments were performed once weekly from weeks 0 to 5. Prior to each test, animals were allowed to acclimate to the testing environment for 30 min. For the PWT measurement, the mice were placed in transparent cages with a wire mesh floor and a selection of von Frey hairs with progressively stronger stimuli. Each mouse underwent five tests for each stimulus strength, and the lowest von Frey hair that elicited three or more paw withdrawals out of five trials was recorded as the PWT. Spontaneous flinching was measured by counting the number of spontaneous flinches during normal movement in an open field. Bone tissue staining Collected mouse bone specimens were fixed in paraformaldehyde at 4℃ for 2 d, then de-calcified using EDTA for two weeks. The tissues were dehydrated in ascending series of ethanol, paraffin-embedded, and sectioned. The sections were then deparaffinized and rehydrated for HE staining (E607318, Sangon Biotech) or TRAP staining following the manufacturer’s instructions. The number of osteoclasts (N. Oc) and bone perimeter (B. Pm) were observed under microscopy and the N.Oc/B.Pm ratio was calculated [27]. Statistical analysis Statistics were performed and diagrams were plotted by Prism 8.0 (GraphPad, La Jolla, CA, USA). All experimental data are presented as the mean ± standard deviation. Differences between groups were analyzed by the two-way analysis of variance (ANOVA) followed by Tukey’s post-hoc test. p < 0.05 was indicative of statistical significance. Results Ketamine suppresses the viability of BC cells and the cells-accelerated osteoclastic differentiation The effect of ketamine on the viability of MDA-MB-231 and ZR-75-1 cells was first examined by the CCK-8 assay. The ketamine conspicuously suppressed the viability of BC cells in a dose-dependent manner (Fig. 1A). The 5-µM ketamine treatment was applied in the subsequent cellular experiments, which is because its IC50 value is closest to that of ketamine for both cell types. This dose of ketamine also significantly blocked the colony formation capacity of the MDA-MB-231 and ZR-75-1 cells (Fig. 1B), and greatly suppressed their migration and invasiveness (Fig. 1C). WB analysis indicated a notable decrease in epithelial-mesenchymal transition (EMT) activity in these cells after ketamine treatment. This was evidenced by increased levels of epithelial marker protein E-cadherin and decreased levels of the mesenchymal markers N-cadherin and Vimentin (Fig. 1D). In a Transwell co-culture system involving BC and RAW 264.7 cells, ketamine also repressed cancer cell-accelerated osteoclastic differentiation of RAW 264.7 cells, as presented by significantly reduced TRAP expression (Fig. 1E). Fig. 1Ketamine suppresses the viability of BC cells and the cells-accelerated osteoclastic differentiation. A, viability of MDA-MB-231 and ZR-75-1 cells after treatment with various doses of ketamine (0, 2, 5, and 10 µM, respectively) for 48 h analyzed by CCK-8 assay (n = 3); B, proliferation of MDA-MB-231 and ZR-75-1 cells after 5 µM of ketamine treatment for 48 h (the same below) determined by colony formation assay (n = 3); C, migration and invasiveness of MDA-MB-231 and ZR-75-1 determined by Transwell assays, scale bar = 200 μm (n = 3); D, protein levels of E-cadherin, N-cadherin, and Vimentin in MDA-MB-231 and ZR-75-1 cells determined by WB analysis (n = 3); E, TRAP expression in a co-culture system of RAW 264.7 cells with MDA-MB-231 and ZR-75-1 cells determined by qPCR analysis (n = 3). Differences were analyzed using two-way ANOVA (A-E). *p < 0.05 Ketamine suppresses the viability of BC cells and the cells-accelerated osteoclastic differentiation. A, viability of MDA-MB-231 and ZR-75-1 cells after treatment with various doses of ketamine (0, 2, 5, and 10 µM, respectively) for 48 h analyzed by CCK-8 assay (n = 3); B, proliferation of MDA-MB-231 and ZR-75-1 cells after 5 µM of ketamine treatment for 48 h (the same below) determined by colony formation assay (n = 3); C, migration and invasiveness of MDA-MB-231 and ZR-75-1 determined by Transwell assays, scale bar = 200 μm (n = 3); D, protein levels of E-cadherin, N-cadherin, and Vimentin in MDA-MB-231 and ZR-75-1 cells determined by WB analysis (n = 3); E, TRAP expression in a co-culture system of RAW 264.7 cells with MDA-MB-231 and ZR-75-1 cells determined by qPCR analysis (n = 3). Differences were analyzed using two-way ANOVA (A-E). *p < 0.05 Ketamine suppresses the expression of SRC that promotes the viability of BC cells We thereafter screened differentially expressed genes (DEGs) in bone metastatic BC versus primary BC tissues by analyzing two GEO datasets GSE103357 and GSE92298, using a p-value threshold of < 0.05 (Fig. 2A). Moreover, we predicted the downstream targets of ketamine using three bioinformatics platforms: Drugbank (https://go.drugbank.com/), SwissTargetPrediction (http://www.swisstargetprediction.ch/index.php), and Super-PRED (https://prediction.charite.de/ index.php). The predicted ketamine targets were compared with the DEGs screened from the GSE103357 and GSE92298 datasets, resulting in a total of 16 overlapping targets (Fig. 2B). A protein-protein interaction (PPI) network based on these candidate factors was constructed via the STRING database (https://cn.string-db.org/), revealing SRC as a core protein in this network (Fig. 2C). Indeed, SRC has been documented to promote bone metastasis in BC [30]. Knockdown of SRC inhibited the colony formation, migration, and invasion capabilities of MDA-MB-231 and ZR-75-1 cells, as well as the osteoclast differentiation of RAW 264.7 cells co-cultured with them (Fig. S1). In MDA-MB-231 and ZR-75-1 cells treated with ketamine, we observed a decrease in SRC protein level (Fig. 2D), indicating that ketamine may alleviate the bone metastasis of BC by suppressing SRC expression. To validate this conjecture, we introduced lentivirus-carried oe-SRC into MDA-MB-231 and ZR-75-1 cells, followed by ketamine treatment. The oe-SRC administration significantly elevated the SRC protein level in these cells (Fig. 2E). The SRC overexpression restored the colony formation ability (Fig. 2F), migration and invasion capabilities (Fig. 2G), as well as the EMT activity (Fig. 2H) of the cells that underwent ketamine treatment. The MDA-MB-231 or ZR-75-1 cells overexpressing SRC also promoted the expression of TRAP in RAW 264.7 cells, indicating enhanced osteoclastic differentiation (Fig. 2I). Fig. 2Ketamine suppresses the expression of SRC that promotes the viability of MDA-MB-231 and ZR-75-1 cells. A, DEGs between bone metastatic and primary BC tissues screened using the GSE103357 and GSE92298 datasets; B, common genes found between the DEGs and the predicted ketamine targets; C, a PPI network of the candidate targets; D-E, protein levels of SRC in MDA-MB-231 and ZR-75-1 cells following ketamine treatment (D) or after oe-SRC pre-transfection (E) determined by WB analysis (n = 3); F, proliferation of MDA-MB-231 and ZR-75-1 cells transfected with oe-SRC and treated with ketamine for 48 h (the same below) determined by colony formation assay (n = 3); G, migration and invasiveness of MDA-MB-231 and ZR-75-1 cells determined by Transwell assays, scale bar = 200 μm (n = 3); H, protein levels of E-cadherin, N-cadherin, and Vimentin in MDA-MB-231 and ZR-75-1 cells determined by WB analysis (n = 3); I, TRAP expression in a co-culture system of RAW 264.7 cells with MDA-MB-231 and ZR-75-1 cells determined by qPCR analysis (n = 3). Differences were analyzed by two-way ANOVA (D-H). *p < 0.05 Ketamine suppresses the expression of SRC that promotes the viability of MDA-MB-231 and ZR-75-1 cells. A, DEGs between bone metastatic and primary BC tissues screened using the GSE103357 and GSE92298 datasets; B, common genes found between the DEGs and the predicted ketamine targets; C, a PPI network of the candidate targets; D-E, protein levels of SRC in MDA-MB-231 and ZR-75-1 cells following ketamine treatment (D) or after oe-SRC pre-transfection (E) determined by WB analysis (n = 3); F, proliferation of MDA-MB-231 and ZR-75-1 cells transfected with oe-SRC and treated with ketamine for 48 h (the same below) determined by colony formation assay (n = 3); G, migration and invasiveness of MDA-MB-231 and ZR-75-1 cells determined by Transwell assays, scale bar = 200 μm (n = 3); H, protein levels of E-cadherin, N-cadherin, and Vimentin in MDA-MB-231 and ZR-75-1 cells determined by WB analysis (n = 3); I, TRAP expression in a co-culture system of RAW 264.7 cells with MDA-MB-231 and ZR-75-1 cells determined by qPCR analysis (n = 3). Differences were analyzed by two-way ANOVA (D-H). *p < 0.05 Overexpression of SRC restores osteoclastic differentiation and tumor bone metastasis in xenograft mouse models To minimize animal sacrifice, only the MDA-MB-231 cell line with a greater aggressive phenotype was selected for animal study. The luciferase-labeled MDA-MB-231 cells were injected into the left ventricle of mice to induce xenograft tumors. According to BLI, the ketamine treatment significantly alleviated tumor burden in the mouse limbs. However, overexpression of SRC in the cells counteracted the role of ketamine, leading to an increased tumor burden (Fig. 3A). The behavioral tests indicated that while ketamine alleviated pain in the mice, SRC overexpression resulted in increased pain (Fig. 3B). The HE staining of mouse bone tissues revealed that ketamine treatment alleviated tumor bone metastasis and increased the number of trabecular bones (Fig. 3C). The TRAP staining and RT-qPCR analyses confirmed that ketamine treatment reduced the number of TRAP-positive cells in the bone tissues (Fig. 3D) and diminished mRNA expression of TRAP, CTR, and CTSK (Fig. 3E). However, the beneficial effects of ketamine were negated by SRC overexpression (Fig. 3C-E). Fig. 3Overexpression of SRC restores osteoclastic differentiation and promotes tumor bone metastasis in xenograft mouse models. A, burden of metastatic tumors in mouse limbs analyzed through BLI (n = 5); B, pain of mice examined by PWT and spontaneous flinching tests (n = 5); C, pathological changes in mouse bone tissues analyzed by HE staining, scale bar = 100 μm (n = 5); D, number of osteoclasts in mouse bone tissues assessed through TRAP staining, scale bar = 100 μm (n = 5); E, mRNA expression of osteoclasts marker TRAP, CTR, and CTSK in mouse bone tissues analyzed using RT-qPCR (n = 5). Differences were analyzed using two-way ANOVA (A-B, E). *p < 0.05 Overexpression of SRC restores osteoclastic differentiation and promotes tumor bone metastasis in xenograft mouse models. A, burden of metastatic tumors in mouse limbs analyzed through BLI (n = 5); B, pain of mice examined by PWT and spontaneous flinching tests (n = 5); C, pathological changes in mouse bone tissues analyzed by HE staining, scale bar = 100 μm (n = 5); D, number of osteoclasts in mouse bone tissues assessed through TRAP staining, scale bar = 100 μm (n = 5); E, mRNA expression of osteoclasts marker TRAP, CTR, and CTSK in mouse bone tissues analyzed using RT-qPCR (n = 5). Differences were analyzed using two-way ANOVA (A-B, E). *p < 0.05 SRC suppresses EGR1 transcription The downstream targets of the transcription factor SRC were predicted using the hTFtarget database (http://bioinfo.life.hust.edu.cn/hTFtarget). The predicted targets were intersected with the above DEGs screened from GSE103357 and GSE92298 datasets, and 92 common genes were obtained (Fig. 4A). These candidate genes were subjected to pathway enrichment analysis using the Metascape system (https://metascape.org/gp/index.html#/main/step1), revealing that they are primarily enriched in the Gastrin signaling pathway (Fig. 4B). This pathway is known to be associated with the proliferation and migration of cancer cells (https://www.wikipathways.org/index.php/ Pathway: WP4659). Among the screened genes, only EGR1 within the gastrin pathway has been previously linked to bone metastasis inhibition in BC [22]. Additionally, analyses using GEPIA (http://gepia.cancer-pku.cn/detail.php) and Starbase (https://starbase.sysu.edu.cn/index.php) confirmed that SRC exhibits a negative correlation with EGR1 expression in BC (Fig. 4C). Thus, we hypothesized that ketamine may influence EGR1 through SRC, impacting osteoclastogenesis and tumor bone metastasis. Indeed, qPCR and WB analyses demonstrated that EGR1 expression levels in MDA-MB-231 and ZR-75-1 cells increased following ketamine treatment but reduced upon SRC overexpression (Fig. 4D). The binding site between SRC and EGR1 promoter was predicted from the hTFtarget system (Fig. 4E), and the direct binding between SRC and the EGR1 promoter was validated through the ChIP-qPCR assay (Fig. 4F). Furthermore, a dual luciferase assay showed that the SRC overexpression in BC cells decreased the luciferase activity of a reporter vector containing the binding sequence of SRC to the EGR1 promoter (Fig. 4G). Fig. 4SRC suppresses EGR1 transcription. A, common genes between the DEGs and the predicted SRC targets; B, pathway enrichment analysis of these candidate common genes; C, an inverse correlation between SRC and EGR1 in BC predicted using the GEPIA and Starbase systems; D, EGR1 mRNA and protein expression in MDA-MB-231 and ZR-75-1 cells with ketamine treatment or oe-SRC pre-transfection determined by qPCR or WB analysis (n = 3); E, binding sequence between SRC and EGR1 promoter predicted in hTFtarget; F, binding relationship between SRC and EGR1 promoter validated using ChIP-qPCR (n = 3); G, transcriptional regulation of SRC on EGR1 validated through a dual luciferase reporter gene assay (n = 3). Differences were analyzed using two-way ANOVA (D, F, G). *p < 0.05 SRC suppresses EGR1 transcription. A, common genes between the DEGs and the predicted SRC targets; B, pathway enrichment analysis of these candidate common genes; C, an inverse correlation between SRC and EGR1 in BC predicted using the GEPIA and Starbase systems; D, EGR1 mRNA and protein expression in MDA-MB-231 and ZR-75-1 cells with ketamine treatment or oe-SRC pre-transfection determined by qPCR or WB analysis (n = 3); E, binding sequence between SRC and EGR1 promoter predicted in hTFtarget; F, binding relationship between SRC and EGR1 promoter validated using ChIP-qPCR (n = 3); G, transcriptional regulation of SRC on EGR1 validated through a dual luciferase reporter gene assay (n = 3). Differences were analyzed using two-way ANOVA (D, F, G). *p < 0.05 Overexpression of EGR1 reduces viability and bone metastasis of BC cells To validate the role of EGR1 in bone metastasis of BC cells, the oe-SRC-transfected MDA-MB-231 and ZR-75-1 cells were further transfected with oe-EGR1, followed by ketamine treatment. The successful upregulation of EGR1 in these cells was confirmed through qPCR and WB assays (Fig. 5A). The EGR1 overexpression conspicuously reduced the colony formation ability (Fig. 5B), migration and invasiveness (Fig. 5C), and the EMT activity (Fig. 5D) in MDA-MB-231 and ZR-75-1 cells that were stimulated by SRC overexpression. In a co-culture system, EGR1 overexpression in BC cells also reduced the osteoclastic differentiation of RAW 264.7 cells (Fig. 5E). These cells were injected into mice intracardially, wherein the EGR1 overexpression reduced the tumor metastatic burden in the mouse limbs (Fig. 5F). Behavioral tests indicated that the EGR1 overexpression alleviated pain in the mice (Fig. 5G). The HE, TRAP staining and RT-qPCR results revealed that EGR1 overexpression reduced metastatic burden, increased the number of trabecular bones, and decreased the number of TRAP-positive cells as well as the expression of TRAP, CTR, and CTSK mRNA in bone tissues (Fig. 5H-J). Fig. 5Overexpression of EGR1 reduces the viability and bone metastasis of MDA-MB-231 and ZR-75-1 cells. A, mRNA and protein expression of EGR1 in MDA-MB-231 and ZR-75-1 cells after oe-SRC and oe-EGR1 transfections and ketamine treatment (the same below) determined by qPCR and WB assays (n = 3); B, proliferation of MDA-MB-231 and ZR-75-1 cells determined using a colony formation assay (n = 3); C, migration and invasiveness of MDA-MB-231 and ZR-75-1 cells determined using Transwell assays, scale bar = 200 μm (n = 3); D, protein levels of E-cadherin, N-cadherin, and Vimentin in cells determined through WB analysis (n = 3); E, TRAP expression in the co-culture system of RAW 264.7 cells with MDA-MB-231 and ZR-75-1 cells determined by qPCR (n = 3); F, burden of metastatic tumors in mouse limbs assessed by BLI (n = 5); G, pain of mice examined using the PWT and spontaneous flinching tests (n = 5); H, pathological changes in mouse bone tissues analyzed using HE staining, scale bar = 100 μm (n = 5); I, number of osteoclasts in mouse bone tissues analyzed using TRAP staining, scale bar = 100 μm (n = 5); J, expression of osteoclasts markers TRAP, CTR, and CTSK mRNA in mouse bone tissues analyzed by RT-qPCR (n = 5). Differences were analyzed using two-way ANOVA (A-G, J). *p < 0.05 Overexpression of EGR1 reduces the viability and bone metastasis of MDA-MB-231 and ZR-75-1 cells. A, mRNA and protein expression of EGR1 in MDA-MB-231 and ZR-75-1 cells after oe-SRC and oe-EGR1 transfections and ketamine treatment (the same below) determined by qPCR and WB assays (n = 3); B, proliferation of MDA-MB-231 and ZR-75-1 cells determined using a colony formation assay (n = 3); C, migration and invasiveness of MDA-MB-231 and ZR-75-1 cells determined using Transwell assays, scale bar = 200 μm (n = 3); D, protein levels of E-cadherin, N-cadherin, and Vimentin in cells determined through WB analysis (n = 3); E, TRAP expression in the co-culture system of RAW 264.7 cells with MDA-MB-231 and ZR-75-1 cells determined by qPCR (n = 3); F, burden of metastatic tumors in mouse limbs assessed by BLI (n = 5); G, pain of mice examined using the PWT and spontaneous flinching tests (n = 5); H, pathological changes in mouse bone tissues analyzed using HE staining, scale bar = 100 μm (n = 5); I, number of osteoclasts in mouse bone tissues analyzed using TRAP staining, scale bar = 100 μm (n = 5); J, expression of osteoclasts markers TRAP, CTR, and CTSK mRNA in mouse bone tissues analyzed by RT-qPCR (n = 5). Differences were analyzed using two-way ANOVA (A-G, J). *p < 0.05 EGR1 overexpression increases CST6 expression, inhibiting viability and pro-osteoclastic effects of BC cells CST6 has reportedly been secreted by BC cells to suppress osteoclastogenesis and tumor bone metastasis [24]. Intriguingly, we identified EGR1 as a candidate transcription regulator of CST6 using the hTFtarget system (Fig. 6A). In MDA-MB-231 and ZR-75-1 cells, the mRNA and protein levels of CST6 were suppressed by SRC overexpression but restored by EGR1 overexpression (Fig. 6B). Likewise, ChIP-qPCR and luciferase assays demonstrated that EGR1 directly bound to the CST6 promoter, activating CST6 transcription (Fig. 6C-D). To validate the role of CST6 in the viability and pro-osteoclastic ability of BC cells, the MDA-MB-231 and ZR-75-1 cells were transfected with lentivirus-carried oe-SRC and oe-CST6. After further treatment with ketamine, both cell types and their culture supernatants (CM) were harvested. The oe-CST6 successfully enhanced CST6 expression in the MDA-MB-231 and ZR-75-1 cells (Fig. 6E). The CST6 upregulation suppressed colony formation (Fig. 6F), migration, invasiveness (Fig. 6G), and EMT activity in these cells (Fig. 6H). Meanwhile, increased protein levels of CST6 were also detected in the CM of MDA-MB-231 and ZR-75-1 cells (Fig. 6I). When RAW 264.7 cells were co-cultured with either MDA-MB-231 or ZR-75-1 cells overexpressing CST6, or with their CM, a significant reduction in TRAP expression was noted (Fig. 6J). Notably, the knockdown of CST6 partially reversed the effects of ketamine (Fig. S2). Fig. 6EGR1 increases CST6 expression to inhibit viability and pro-osteoclastic effect of BC cells. A, putative binding sequence between EGR1 as a transcription factor and CST6 predicted using hTFtarget; B, mRNA and protein levels of CST6 in MDA-MB-231 and ZR-75-1 cells with oe-SRC and oe-CST6 transfection and ketamine treatment determined by qPCR and WB analyses; C, binding between EGR1 and CST6 promoter validated through ChIP-qPCR analysis (n = 3); D, transcriptional regulation of EGR1 on CST6 validated using a luciferase assay (n = 3); E, mRNA and protein expression of CST6 in MDA-MB-231 and ZR-75-1 cells transfected with oe-SRC and oe-CST6 (the same below) examined using qPCR and WB analyses; F, proliferation of MDA-MB-231 and ZR-75-1 cells determined through a colony formation assay (n = 3); G, migration and invasiveness of MDA-MB-231 and ZR-75-1 cells determined using Transwell assays, scale bar = 200 μm (n = 3); H, protein levels of E-cadherin, N-cadherin, and Vimentin in cells determined through WB analysis (n = 3); I, protein level of CST6 in the CM of MDA-MB-231 and ZR-75-1 cells examined through WB analysis (n = 3); J, TRAP expression in RAW 264.7 cells after co-culture with MDA-MB-231 and ZR-75-1 cells or with the CM of cells determined using qPCR analysis (n = 3). Differences were compared using two-way ANOVA (B-J). *p < 0.05 EGR1 increases CST6 expression to inhibit viability and pro-osteoclastic effect of BC cells. A, putative binding sequence between EGR1 as a transcription factor and CST6 predicted using hTFtarget; B, mRNA and protein levels of CST6 in MDA-MB-231 and ZR-75-1 cells with oe-SRC and oe-CST6 transfection and ketamine treatment determined by qPCR and WB analyses; C, binding between EGR1 and CST6 promoter validated through ChIP-qPCR analysis (n = 3); D, transcriptional regulation of EGR1 on CST6 validated using a luciferase assay (n = 3); E, mRNA and protein expression of CST6 in MDA-MB-231 and ZR-75-1 cells transfected with oe-SRC and oe-CST6 (the same below) examined using qPCR and WB analyses; F, proliferation of MDA-MB-231 and ZR-75-1 cells determined through a colony formation assay (n = 3); G, migration and invasiveness of MDA-MB-231 and ZR-75-1 cells determined using Transwell assays, scale bar = 200 μm (n = 3); H, protein levels of E-cadherin, N-cadherin, and Vimentin in cells determined through WB analysis (n = 3); I, protein level of CST6 in the CM of MDA-MB-231 and ZR-75-1 cells examined through WB analysis (n = 3); J, TRAP expression in RAW 264.7 cells after co-culture with MDA-MB-231 and ZR-75-1 cells or with the CM of cells determined using qPCR analysis (n = 3). Differences were compared using two-way ANOVA (B-J). *p < 0.05 Overexpression of CST6 suppresses tumor bone metastasis in vivo The MDA-MB-231 and ZR-75-1 cells transfected with oe-SRC and oe-CST6 were intracardially injected into mice as well. As expected, the CST6 overexpression reduced the metastatic burden in the mouse limbs (Fig. 7A), which exhibited decreased PWT and spontaneous flinches (Fig. 7B). The HE staining identified that the CST6 overexpression alleviated metastatic burden and increased the number of trabecular bones in the bone tissues (Fig. 7C). The TRAP staining and RT-qPCR confirmed that the number of TRAP-positive cells and the expression of TRAP, CTR, and CTSK mRNA in bone tissues was reduced by oe-CST6 as well (Fig. 7D-E). Fig. 7Downregulation of EGR1 reduces viability and bone metastasis of MDA-MB-231 cells. A, burden of metastatic tumors in mouse limbs after intracardial injection of MDA-MB-231 cells transfected with oe-SRC and oe-CST6 analyzed by BLI (n = 5); B, pain of mice examined using PWT and spontaneous flinching tests (n = 5); C, pathological changes in mouse bone tissues analyzed through HE staining, scale bar = 100 μm (n = 5); D, number of osteoclasts in mouse bone tissues analyzed using TRAP staining, scale bar = 100 μm (n = 5); E, expression of osteoclasts markers TRAP, CTR, and CTSK mRNA in mouse bone tissues analyzed by RT-qPCR (n = 5). Differences were analyzed using two-way ANOVA (A-B, E). *p < 0.05 Downregulation of EGR1 reduces viability and bone metastasis of MDA-MB-231 cells. A, burden of metastatic tumors in mouse limbs after intracardial injection of MDA-MB-231 cells transfected with oe-SRC and oe-CST6 analyzed by BLI (n = 5); B, pain of mice examined using PWT and spontaneous flinching tests (n = 5); C, pathological changes in mouse bone tissues analyzed through HE staining, scale bar = 100 μm (n = 5); D, number of osteoclasts in mouse bone tissues analyzed using TRAP staining, scale bar = 100 μm (n = 5); E, expression of osteoclasts markers TRAP, CTR, and CTSK mRNA in mouse bone tissues analyzed by RT-qPCR (n = 5). Differences were analyzed using two-way ANOVA (A-B, E). *p < 0.05 Discussion The bone microenvironment provides a conducive setting for various malignancies to establish, survive, and proliferate with BC being a significant type that often leads to bone metastases [7]. This study unravels the suppressive effects of ketamine on the viability of BC cells and the cells-induced osteoclastogenesis and bone metastases associated with BC. The tumor-suppressive and pain-relieving effects are attributable to the specific suppression of SRC and restoration of the EGR1/CST6 axis. The function of ketamine in managing cancer-related pain remains a topic of debate. In the work by Emma and colleagues, routine administration of ketamine is not recommended for the management of cancer pain, though it can serve as an effective drug analgesic for non-cancer pains [9]. A randomized double-blind trial indicated that ketamine offered no significant clinical advantage over placebo when used alongside opioids for cancer pain management [31]. Conversely, a subsequent review by Bredlau et al. summarized that ketamine provides a moderate analgesic effect for refractory cancer pain [32]. Clayton and colleagues also highlighted in their review that ketamine is effective in alleviating chronic pain, acute pain, and cancer-related neuropathic pain [14]. Intriguingly, ketamine exhibited stronger effects than opioids in relieving acute postoperative pain in BC patients [33]. The primary mechanism of action of ketamine in analgesia involves antagonizing the NMDA receptor, which is known to contribute to the development of opioid tolerance [34]. Ketamine administered at a dose of 40 mg/kg demonstrated an analgesic effect against bone cancer pain without overt side effects compared to another NMDA receptor antagonist, MK-801 [35]. Importantly, by inhibiting the NMDA receptor, ketamine has been reported to suppress RANKL-induced osteoclastic differentiation of bone marrow macrophages [36], indicating that ketamine may alleviate pain by reducing osteoclastogenesis and bone metastasis. Some studies suggest that long-term, high-dose ketamine use may lead to addiction and potentially enhance breast cancer progression [37, 38]. However, current research indicates that short-term, low-dose use of ketamine can suppress the development of breast cancer [15]. In this work, we validated that treatment with ketamine (5 µM) significantly suppressed the proliferation, migration, and invasiveness, EMT activity, and the pro-osteoclastic role of the two BC cell lines. In vivo, the ketamine treatment (10 mg/kg) reduced the bone metastasis burden in mice and showed significant analgesic effects. Beyond its pain management properties, ketamine has also been implicated in directly suppressing cancer progression by suppressing proliferation and resistance to death [39]. Subsequently, we explored the molecular targets affected by ketamine. Through the analysis of the GSE103357 and GSE92298 datasets, along with data from Drugbank and establishment of a PPI network, we identified SRC as a core target protein of ketamine. SRC is usually hyperactivated in the majority of solid tumors and plays a crucial role in regulating cell proliferation, tumor angiogenesis, metastasis, and EMT through various oncogenic signaling pathways (e.g. PI3K/Akt, β-catenin, and Ras/MAPK pathways) [40]. This is particularly relevant for BC, as activation of SRC-dependent pathways has been closely correlated with tumor growth in the bone marrow and the potential for bone metastasis [30]. The SRC in bone metabolism regulation is partly attributable to its promoting effect on osteoclastogenesis and subsequent bone metastasis [41, 42]. Notably, we observed that the ketamine treatment suppressed SRC expression in MDA-MB-231 and ZR-75-1 cells. Functional rescue assays revealed that the restoration of SRC levels in the two BC cell lines negated the effects of ketamine, leading to increased cell proliferation and metastasis, heightened osteoclastic differentiation of RANKL-induced RAW 264.7 cells, as well as increased osteoclastogenesis, bone metastasis burden, and cancer pain in nude mice with xenograft tumors. When exploring the downstream targets of SRC, we predicted the target genes of SRC in the hTFtarget system and compared the results with the DEGs from GSE103357 and GSE92298 datasets. We identified 92 intersecting genes that were enriched in the gastrin signaling. Notably, low serum levels of gastrin have been linked to the development of estrogen receptor-positive BC [43]. Moreover, EGR1 is the sole member in the gastrin signaling pathway suggested to promote angiogenic and osteoclastogenic factors, which regulate bone microenvironment and facilitate cancer metastasis [44]. In BC, EGR1 has been identified as a tumor suppressor, with low expression levels correlating with poor patient prognosis [45, 46]. It has been found to suppress the migration and metastasis of BC cells by repressing Nm23-H1 transcription [47], and its upregulation has been potentially linked to reduced skeletal metastasis in BC [22]. In our study, we confirmed the binding between SRC and EGR1 promoter and identified that the EGR1 expression increased in MDA-MB-231 and ZR-75-1 cells after ketamine treatment but reduced following SRC overexpression. Moreover, through the hTFtarget system, we identified and validated CST6 as a target of EGR1. We focused on CST6 because it has been reported to suppress the proliferation and mobility of BC cells and to reduce osteolytic metastasis by reducing osteoclastogenesis [24]. A study by Li et al. also demonstrates that cancer cell-derived CST6 enters osteoclasts via endocytosis and inhibits osteoclast maturation through a CTSB/SPHK1 axis, thereby reducing osteoclastogenesis and osteolytic bone metastasis in BC [26]. Our findings indicate that upregulating either EGR1 or CST6 in MDA-MB-231 and ZR-75-1 cells counteracted the function of oe-SRC, which suppressed cell proliferation and metastasis and their pro-osteoclastic effects. In vivo assays also revealed that the EGR1 or CST6 overexpression in BC cells reduced bone metastasis and alleviated pain in mice. Collectively, this work demonstrates that ketamine alleviates BC cell-induced osteoclastogenesis and tumor bone metastasis by suppressing SRC and restoring the EGR1/CST6 axis (Fig. 8). This study provides supportive evidence for the potential application of ketamine in managing cancer-related bone pain in BC. Moreover, targeted inhibition of SRC or activation of the EGR1/CST6 axis might be promising strategies for pain relief in cancer patients. Fig. 8Graphical abstract. Ketamine treatment suppresses SRC expression, restoring transcriptional activity and protein levels of EGR1. The EGR1 upregulation results in an elevation of CST6 transcription and expression, consequently suppressing proliferation, migration, invasion, EMT, and the pro-osteoclastic effect of BC cells in vitro. The EGR1 and CST6 restoration in cancer cells also suppresses osteoclastogenesis and tumor bone metastasis in xenograft mouse models Graphical abstract. Ketamine treatment suppresses SRC expression, restoring transcriptional activity and protein levels of EGR1. The EGR1 upregulation results in an elevation of CST6 transcription and expression, consequently suppressing proliferation, migration, invasion, EMT, and the pro-osteoclastic effect of BC cells in vitro. The EGR1 and CST6 restoration in cancer cells also suppresses osteoclastogenesis and tumor bone metastasis in xenograft mouse models Supplementary Information Supplementary Material 1. Supplementary Material 1. Supplementary Material 2. Supplementary Material 2. Supplementary Material 3. Supplementary Material 3. Supplementary Material 4. Supplementary Material 4. Supplementary Material 5. Supplementary Material 5.